NOAL

  • Home
  • Welcome
  • Neuronal Injury & Repair (NIR) Laboratory
  • Science Behind Alzheimer’s Disease
  • Protect Yourself
  • Latest News & Researches
  • Events
  • Contact Us

Author Archives: NOAL

What Alzheimer’s Does to The Brain!

Posted on December 1, 2017 by NOAL Posted in Welcome .

Accumulation of the protein aggregates is the leading cause of cellular dysfunction in neurodegenerative diseases. In physiological situation, the protein misfolding is sensed by the cellular control systems as a threat to the survival of neurons, which will be followed by an immediate neuronal response. Any delay to detect the misfolded proteins, may result in neuronal deterioration and progression of neurodegenerative disorders. Alzheimer’s disease (AD), the most common form of dementia among the elderly and the third leading cause of death in adults is associated with two main lesions, both as a consequence of protein aggregation: extracellular plaques made of beta-amyloid (Aβ) and intracellular neurofibrilary tangles (NFT) made of tau protein.

A large plaques of Beta amyloid (red) surrounds a neuron which is highly positive for phosphorylated m-TOR (green). Phosphorylated m-TOR reduces cell ability of autophagy, a critical process to clear beta-amyloid. Accumulation of tau protein in Neurofibrillary tangles (cyan) could be seen in another neuron above beta amyloid plaque.  Image Credit: Neuronal Injury & Repair (NIR) Laboratory; Dr. Shohreh Majd)

 

Although the process of neuronal death is a common feature in Alzheimer’s disease, underlying mechanisms are still under investigation. In this scenario, Aβ and Neurofibrillary tangles  are considered as the main neurotoxic proteins to initiate neurodegeneration.

(Video Credit: Nature Video)

Leave a comment .

Stop Alzheimer’s Before it Starts!

Posted on September 22, 2017 by NOAL Posted in Welcome .

The science reveals that those who eschew processed foods and choose whole, real-food options have the least decline in mental faculty

 

Till the time that a breakthrough could be found to cure Alzheimer’s disease, the chance of having it after 85 is almost 50% (1 in 2 people). While most of the current researches are focused on finding a cure, after developing the symptoms, it’s getting more clear that applying preventive strategies must begin long time before the pathology of  disease reaching to the stage of presenting clinical symptoms.

Image result for Alzheimer's Association cancer diabetes 2030

In 2016, around 700,000 Americans at 65 or older died with Alzheimer‘s disease, which many of them died because of Alzheimer‘s disease’s complications.  Therapeutic strategies usually don’t change the disease progression, especially when it is considered that the brain is already severely damaged by the time of starting treatment.  some of the drugs have even shown the serious side effects such as brain inflammation. That indeed highlights the importance of applying preventive methods and strategies, ways before developing clinical symptoms.

 

Image result for brain shrinkage alzheimer's

What to do?

A recent paper in Cerebrum Journal has described the 4 main preventive strategies for Alzheimer’s disease.

  1. Healthy diet (more natural, less processed) food plus supplements (multivitamins, supplements of omega-3 oils,…)
  2. Physical and mental activity
  3. Yoga and meditation
  4. Psychological well-being

It seems that choosing a healthy life style is the only way that we have currently to live a long life and going to a healthy aging with no fear of Alzheimer’s disease.

 

Reference:

Khalsa D. and Perry G. The Four Pillars of Alzheimer’s Prevention Cerebrum 2017 cer-03-17.

Leave a comment .

Knowing Alzheimer’s Disease

Posted on August 6, 2017 by NOAL Posted in Welcome .

Alzheimer’s disease is the most common reason for the death of brain cells due to a brain disease. The life expectancy is considerably increasing all around the world, and with that the incidence of Alzheimer’s disease, the main neurodegenerative disorders during aging. The prevalence of AD is growing from 25 million in 2011 to an estimated number of 50 million in 2030, with only 5 % of the entire cases have a genetic predisposal background.

The disease was explained for the first time, by German neuropathologist, Alois Alzheimer, while he showed the unusual presence of some fibrilar structure in the brain of her patient, Auguste Deter, after death.

Related image

Further studies on the brain of patients with Alzheimer’s disease after death, revealed the accumulation of some proteins in the form of aggregates. That includes two major proteins of beta-Amyloid (Aβ) and phosphorylated tau peptide in the form of cellular tangles, known as neurofibrillary tangle (NFT). These two peptides now are considered as the main signatures of Alzheimer’s disease.

Postmortem tissue sample from an AD patient brain reveals AD pathology including amyloid-beta plaques and Tau tangles (Photo credit Dr. Shohreh Majd).

Beat Amyloid Cascade  and Tau Hypotheses:

In 1984 Glenner and Wong reveled the structure of Aβ as the main component of senile plaques.  This discovery led to beta amyloid cascade hypothesis, suggesting Aβ deposition as the first trigger for AD pathogenesis and generating its other hallmarks such as NFTs, neuro-inflammation, synaptic loss and eventually a massive neuronal death This hypothesis was supported by the fact that the amyloid precursor protein (APP) gene on chromosome 21, is mutated in many cases of familial AD. Besides, mutated forms of PS1 and PS2, enhances Aβ production from APP, and were suggested as the main trigger of AD pathology in the other types of familiar AD. Since Familial and sporadic AD shared the same pathological hallmarks and clinical manifestation, and because of that, Aβ cascaded hypothesis has been used to explain the pathogenesis in both types of AD.

Numerous studies suggested a dominant role for tauopathy as the upstream initiator of AD pathogenesis. Hyperphosphorylation of tau as a microtubule associated protein reduces its glue-like ability to bind the globular elements of actin to each other to form acting tubular structure. Instead hyperphosphoryalted tau, clumps and build up NFT , the second AD hallmark, inside the cells. Co-presence of NFTs, neurodegeneration and memory impairment in animal and human studies and high level of correlation between p-tau in AD patients’ cerebrospinal fluid (CSF) and the disease progression have brought more evidence to support tau hypothesis as the other convincing explanation for AD pathology.

Related image

The progressive nature of this disease slowly kills the brain cells, which starts from the centre of memory, hippocampus. The damage will spread to the other brain regions and impairs the thinking and analyzing skills of the patient. Most of the patients begin to show the symptoms in their mid-60s with continues progress of disease condition. In the end stage of disease the brain shrinks significantly, as it has lost many of its cells and the patient would requires a constant care as carrying out the normal daily activities, even the simple tasks will be impossible.

Image result for alzheimer stages

Image credit: Senior Directory

Alzheimer’s Disease Classification

Familial Alzheimer’s Disease:

Familial Alzheimer’s Disease (FAD, also known as early onset), usually before 60 (usually between 50-60) and includes 5% of the total Alzheimer’s cases. In FAD  mutation in one or more of three genes (amyloid precursor protein (APP), presenilin 1 (PS 1) and presenilin 2 (PS 2)) is the underlying cause for AD pathology. The consequence of either of the mutations increases the accumulation of beta amyloid (Aβ) peptides in an aggregated insoluble form of senile plaques, a main hallmark for Alzheimer’s disease.

Sporadic Alzheimer’s Disease:

Sporadic AD (SAD) contains 95% of all AD cases and has unknown etiology. SAD pathogenesis probably made of a combination of different genetics and environmental factors, such as (but not limited to) aging, hypertension, hypercholesterolemia, APOE ɛ4,  smoking, diabetes and head injury.

 

References:

  1. Glenner GG, Wong CW. Biochem Biophys Res Commun. 1984 May 16;120(3):885-90
  2. Reitz C. et al. Nat Rev Neurol. 2011 Mar;7(3):137-52. doi: 10.1038
  3. Majd S. et al, Brain Res. 2008 Jul 7;1218:224-9. doi: 10.1016
  4. Majd S. et al. BMC Neurosci. 2015 Oct 23;16:69. doi: 10.1186
  5. Duthey B. (2013). Background Paper 6.11. Alzheimer Disease and other Dementias. 6.11:4-74
  6. Herrup K. J Neurosci. 2010 Dec 15;30(50):16755-62. doi: 10.1523
3 Comments .

Recent Posts

  • What Alzheimer’s Does to The Brain!
  • Stop Alzheimer’s Before it Starts!
  • Knowing Alzheimer’s Disease

Meta

  • Log in
  • Comments RSS

CyberChimps WordPress Themes

© NOAL 2017